Dulanermin (Not yet branded)
Other Medications
Description
Dulanermin is a recombinant human TRAIL (TNF-related apoptosis-inducing ligand) protein designed to selectively induce apoptosis in cancer cells. In colorectal cancer treatment, dulanermin is administered in combination with standard chemotherapy regimens including FOLFIRI, FOLFOX, and targeted agents like cetuximab and bevacizumab. The drug aims to enhance the cytotoxic effects of conventional chemotherapy by activating death receptor-mediated apoptotic pathways in malignant cells.
Mechanism of Action
Dulanermin binds to and activates death receptors DR4 and DR5 on the surface of cancer cells, triggering the extrinsic apoptotic pathway through caspase cascade activation. This mechanism allows for selective targeting of malignant cells while sparing normal healthy tissue, as cancer cells typically have higher expression of death receptors and defective apoptotic machinery.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | IV |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.